IBI-310

Overview

IBI-310 is an investigational anti-CTLA-4 monoclonal antibody targeting CTLA4. It is evaluated in combination with sintilimab (anti-PD-1) for nasopharyngeal carcinoma (NPC) and other solid tumors.

Evidence in the corpus

• Anti-CTLA-4 IBI-310 in combination with sintilimab is listed as an investigational strategy targeting compensatory CTLA-4 checkpoint upregulation in PD-1/PD-L1-refractory NPC PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.